WRN

Bifunctional 3'-5' exonuclease/ATP-dependent helicase WRN

5,831 patent compounds predicted against WRN, 4,106 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL6080735	0.51	4/20
SCHEMBL12267832	0.50	4/20
SCHEMBL13710198	0.49	4/20
SCHEMBL2030731	0.76	3/20
SCHEMBL12642191	0.76	3/20
SCHEMBL5444646	0.74	3/20
SCHEMBL6323159	0.54	3/20
SCHEMBL11851358	0.43	3/20
SCHEMBL4191033	0.41	3/20
SCHEMBL13710191	0.39	3/20
SCHEMBL4429683	0.38	3/20
SCHEMBL11875081	0.80	2/20
SCHEMBL5454402	0.71	2/20
SCHEMBL7196311	0.70	2/20
SCHEMBL13912189	0.61	2/20
SCHEMBL13912186	0.59	2/20
SCHEMBL5542748	0.54	2/20
SCHEMBL6379151	0.54	2/20
SCHEMBL3476471	0.52	2/20
Resequinil (SCHEMBL677466)	0.51	2/20

Germline variants in WRN on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full WRN gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to WRN by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)	PHASE3	COMPLETED
Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency	PHASE2/PHASE3	RECRUITING
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients	PHASE3	COMPLETED
Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients	PHASE3	COMPLETED
Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin	PHASE2	COMPLETED
Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA)	PHASE1/PHASE2	COMPLETED
Reverse Transcriptase Inhibitors in AGS	PHASE2	COMPLETED
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies	PHASE1/PHASE2	RECRUITING
Effects of Vitamin B3 in Patients With Ataxia Telangiectasia	PHASE2	COMPLETED
Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment	PHASE2	ACTIVE_NOT_RECRUITING
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors	PHASE1/PHASE2	RECRUITING
Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer	PHASE2	ACTIVE_NOT_RECRUITING
A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)	PHASE2	COMPLETED
Phase II ABT-888 With Cyclophosphamide	PHASE2	COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas	PHASE1	COMPLETED
Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.	PHASE1	ACTIVE_NOT_RECRUITING
Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer	PHASE1	COMPLETED
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors	PHASE1	RECRUITING
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors	PHASE1	ACTIVE_NOT_RECRUITING
ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems	PHASE1	WITHDRAWN
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors	PHASE1	COMPLETED
Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors	PHASE1	COMPLETED
Efficacy and Adverse Effects of Olaparib in Ovarian Cancer.	nan	UNKNOWN
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients	nan	COMPLETED
Application of Genetic Polymorphisms of DNA Repair in The Prediction of Prostate Cancer Susceptibility and Its Clinical Outcome	nan	UNKNOWN
Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer	nan	UNKNOWN
Biological Aging Hallmarks-Guided Integrative TCM and Conventional Medicine in Post-Treatment Unexplained Female Infertility	nan	RECRUITING
Efficacy and Adverse Effects of Niraparib in Ovarian Cancer.	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a WRN binder may also engage these)

Protein	Name	Similarity
O93530	—	1.000	O93530 →
O09053	—	1.000	O09053 →
Q9FT70	—	0.996	Q9FT70 →
Q9FT69	—	0.995	Q9FT69 →
Q04692	—	0.993	Q04692 →
Q9SP32	—	0.992	Q9SP32 →
A6QQR4	—	0.991	A6QQR4 →
Q0PCS3	—	0.991	Q0PCS3 →
Q5FWF4	—	0.991	Q5FWF4 →
F4IV45	—	0.991	F4IV45 →
DHX29	ATP-dependent RNA helicase DHX29	0.991	landscape →
Q9H4L7	—	0.991	Q9H4L7 →
D3Z9Z9	—	0.991	D3Z9Z9 →
POLQ	DNA polymerase theta	0.990	landscape →
E1B7X9	—	0.990	E1B7X9 →
F4I9Q5	—	0.990	F4I9Q5 →
Q6NZP1	—	0.990	Q6NZP1 →
F4JAA5	—	0.990	F4JAA5 →
Q8W103	—	0.990	Q8W103 →
Q6P158	—	0.990	Q6P158 →
A3EWL3	—	0.990	A3EWL3 →
Q8L840	—	0.989	Q8L840 →
Q9Z2R9	—	0.989	Q9Z2R9 →
Q9C6G0	—	0.989	Q9C6G0 →
Q9NRZ9	—	0.989	Q9NRZ9 →
D3ZA12	—	0.989	D3ZA12 →
Q6Q4D0	—	0.989	Q6Q4D0 →
Q6GM53	—	0.989	Q6GM53 →
A3KFM7	—	0.989	A3KFM7 →
Q5FWR0	—	0.989	Q5FWR0 →